Azathioprine — Membership Pricing

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Crohn's Disease

• Budesonide
• Mesalamine
• Methotrexate
• Prednisone

Also listed for Ulcerative Colitis

• Sulfasalazine

Other medications in Gastrointestinal

• Dapsone
• Dicyclomine
• Esomeprazole
• Famotidine
• Hyoscyamine
• Lansoprazole
• Loperamide
• Omeprazole

What Azathioprine is approved for (FDA label)

Azathioprine is indicated as an adjunct for the prevention of rejection in renal homotransplantation. It is also indicated for the management of active rheumatoid arthritis to reduce signs and symptoms. Renal Homotransplantation: Azathioprine is indicated as an adjunct for the prevention of rejection in renal homotransplantation. Experience with over 16,000 transplants shows a 5-year patient survival of 35% to 55%, but this is dependent on donor, match for HLA antigens, anti-donor or anti-B-cell alloantigen antibody, and other variables. The effect of azathioprine on these variables has not been tested in controlled trials. Rheumatoid Arthritis: Azathioprine is indicated for the treatment of active rheumatoid arthritis (RA) to reduce signs and symptoms.

Source: Read the full FDA label on DailyMed. Label effective date: May 5, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Azathioprine (FDA label)

WARNING-MALIGNANCY Chronic immunosuppression with azathioprine, a purine antimetabolite increases risk of malignancy in humans. Reports of malignancy include post-transplant lymphoma and hepatosplenic T-cell lymphoma (HSTCL) in patients with inflammatory bowel disease. Physicians using this drug should be very familiar with this risk as well as with the mutagenic potential to both men and women and with possible hematologic toxicities. Physicians should inform patients of the risk of malignancy with azathioprine. See WARNINGS .

Source: FDA prescribing information (DailyMed). Set ID: 5116b22b-1460-5535-e063-6394a90acbe5. SPL document ID: 5116b232-1893-9012-e063-6294a90a06f6. Label effective date: May 5, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Azathioprine (FDA label)

The principal and potentially serious toxic effects of azathioprine are hematologic and gastrointestinal. The risks of secondary infection and malignancy are also significant (see WARNINGS ). The frequency and severity of adverse reactions depend on the dose and duration of azathioprine as well as on the patient’s underlying disease or concomitant therapies. The incidence of hematologic toxicities and neoplasia encountered in groups of renal homograft recipients is significantly higher than that in studies employing azathioprine for rheumatoid arthritis.

Source: FDA prescribing information (DailyMed). Set ID: 5116b22b-1460-5535-e063-6394a90acbe5. SPL document ID: 5116b232-1893-9012-e063-6294a90a06f6. Label effective date: May 5, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Azathioprine (FDA label)

Azathioprine should not be given to patients who have shown hypersensitivity to the drug. Azathioprin should not be used for treating rheumatoid arthritis in pregnant women. Patients with rheumatoid arthritis previously treated with alkylating agents (cyclophosphamide, chlorambucil, melphalan, or others) may have a prohibitive risk of malignancy if treated with azathioprine.

Source: FDA prescribing information (DailyMed). Set ID: 5116b22b-1460-5535-e063-6394a90acbe5. SPL document ID: 5116b232-1893-9012-e063-6294a90a06f6. Label effective date: May 5, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Azathioprine (FDA label)

Use with xanthine oxidase (XO) inhibitors: One of the pathways for inactivation of azathioprine is inhibited by XO inhibitors (allopurinol or febuxostat). Patients receiving azathioprine and allopurinol concomitantly should have a dose reduction of azathioprine, to approximately 1/3 to 1/4 the usual dose. Concomitant use of azathioprine with febuxostat is not recommended. Inhibition of XO may cause increased plasma concentrations of azathioprine or its metabolite, 6-MP, leading to toxicity. It is recommended that a further dose reduction or alternative therapies be considered for patients with low or absent TPMT activity receiving azathioprine and xanthine oxidase inhibitors because both TPMT and XO inactivation pathways are affected (see CLINICAL PHARMACOLOGY, WARNINGS, PRECAUTIONS: Laboratory Tests and ADVERSE REACTIONS sections). Use with Aminosalicylates: There is in vitro evidence that aminosalicylate derivatives (e.g., sulphasalazine, mesalazine, or olsalazine) inhibit the TPMT enzyme. Concomitant use of these agents with azathioprine should be done with caution.

Source: FDA prescribing information (DailyMed). Set ID: 5116b22b-1460-5535-e063-6394a90acbe5. SPL document ID: 5116b232-1893-9012-e063-6294a90a06f6. Label effective date: May 5, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.